Cargando…

Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review

BACKGROUND AND OBJECTIVE: Denosumab is a valuable and safe therapy for skeletal disorders in adults and has received regulatory approval to treat osteoporosis and bone metastases. However, denosumab is not licensed for pediatric use due to a lack of high-quality prospective research on children. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Daoxi, Tang, Xueyang, Shi, Qianyu, Wang, Ruifeng, Ji, Tao, Tang, Xiaodong, Guo, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080477/ https://www.ncbi.nlm.nih.gov/pubmed/37035391 http://dx.doi.org/10.21037/tp-22-276

Ejemplares similares

Targeting the tumour microenvironment: denosumab, a new RANKL inhibitor
por: Coleman, RE
Publicado: (2009)

Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
por: Zhang, Ning, et al.
Publicado: (2020)

Treatment of Stage I-III Hip Joint Tuberculosis With Open Surgical Debridement and Hip Spica in Children: A Retrospective Study
por: Yang, Lei, et al.
Publicado: (2022)

Multicentric carpotarsal osteolysis syndrome (MCTO) with generalized high bone turnover and high serum RANKL: Response to denosumab
por: Regev, Ravit, et al.
Publicado: (2021)

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
por: Schieferdecker, Aneta, et al.
Publicado: (2014)

Denosumab Attenuates Glucolipotoxicity-Induced β-Cell Dysfunction and Apoptosis by Attenuating RANK/RANKL Signals
por: Lin, Sheng-Chieh, et al.
Publicado: (2023)

Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials
por: Lu, Junjie, et al.
Publicado: (2023)

Denosumab inhibits MCF-7 cell line-induced spontaneous osteoclastogenesis via the RANKL/MALAT1/miR-124 axis
por: Feng, Qi, et al.
Publicado: (2020)

Pathological dislocation of the hip due to coxotuberculosis in children: a 29-case report
por: Jiang, Xin, et al.
Publicado: (2014)

Retraction Note: Pathological dislocation of the hip due to coxotuberculosis in children: a 29-case report
por: Jiang, Xin, et al.
Publicado: (2015)

Safety and efficacy of denosumab in the treatment of pulmonary metastatic giant cell tumor of bone
por: Luo, Yi, et al.
Publicado: (2018)

Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
por: Anastasilakis, Athanasios D., et al.
Publicado: (2021)

Prognostic Value and Quantitative CT Analysis in RANKL Expression of Spinal GCTB in the Denosumab Era: A Machine Learning Approach
por: Wang, Qizheng, et al.
Publicado: (2022)

Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

MON-LB72 Multicentric Carpotarsal Osteolysis Syndrome (MCTO) Has a Generalized High Turnover Bone Phenotype, High S RANKL and Responds to Denosumab
por: Regev, Ravit, et al.
Publicado: (2020)

Effect of denosumab, a human monoclonal antibody of receptor activator of nuclear factor kappa-B ligand (RANKL), upon glycemic and metabolic parameters: Effect of denosumab on glycemic parameters
por: Abe, Ichiro, et al.
Publicado: (2019)

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells
por: Cuyàs, Elisabet, et al.
Publicado: (2017)

Preoperative Denosumab may increase the Risk of Local Recurrence of Giant-cell Tumor of Bone Treated with Curettage: A Systematic Review and Meta-analysis
por: Zhao, Yongzhao, et al.
Publicado: (2021)

Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review
por: Kendler, David L., et al.
Publicado: (2021)

Impact of denosumab on bone mass in cancer patients
por: Brown-Glaberman, Ursa, et al.
Publicado: (2013)

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Bone Health and Denosumab Discontinuation in Oncology Populations
por: Cheung, Yee-Ming Melody, et al.
Publicado: (2022)

Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males
por: Findlay, David, et al.
Publicado: (2008)

The outcome of loose bone fragments in pediatric supracondylar humerus fractures: a retrospective study
por: Yang, Lei, et al.
Publicado: (2020)

Chondroblastoma’s Lung Metastases Treated with Denosumab in Pediatric Patient
por: Focaccia, Marco, et al.
Publicado: (2021)

TREM-1 Is Upregulated in Experimental Periodontitis, and Its Blockade Inhibits IL-17A and RANKL Expression and Suppresses Bone loss
por: Bostanci, Nagihan, et al.
Publicado: (2019)

RANKL blockade alleviates peri-implant bone loss and is enhanced by anti-inflammatory microRNA-146a through TLR2/4 signaling
por: Pan, Keqing, et al.
Publicado: (2020)

The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies
por: Xu, Jiuhui, et al.
Publicado: (2023)

Denosumab Use in Chronic Kidney Disease Associated Osteoporosis: A Narrative Review
por: Abduelkarem, Abduelmula R, et al.
Publicado: (2023)

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
por: Li, Huiping, et al.
Publicado: (2023)

Use of a 3D-Printed Patient-Specific Surgical Jig and Ready-Made Total Sacral Endoprosthesis for Total Sacrectomy and Reconstruction
por: Shi, Qianyu, et al.
Publicado: (2021)

En bloc resection and reconstruction of a huge chondrosarcoma involving multilevel upper thoracic spine and chest wall: case report
por: Tang, Xiaodong, et al.
Publicado: (2021)

The Effect of Denosumab on Bone Mass in Super Elderly Patients
por: Jeong, Chaiho, et al.
Publicado: (2020)

Amelioration of Paget Disease of Bone After Denosumab for Osteopenia
por: Kamalumpundi, Vijayvardhan, et al.
Publicado: (2023)

RANK, RANKL and osteoprotegerin in bone biology and disease
por: Wright, H. L., et al.
Publicado: (2009)

Regulation of RANKL signaling in arthritic bone destruction
por: Takayanagi, H
Publicado: (2003)

RANKL-induced M1 macrophages are involved in bone formation
por: Huang, Rong, et al.
Publicado: (2017)

RO4929097 regulates RANKL-induced osteoclast formation and LPS-mediated bone resorption
por: Huang, Tao, et al.
Publicado: (2021)

Clinical utility of denosumab for treatment of bone loss in men and women
por: Adler, Robert A, et al.
Publicado: (2011)

Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller, Channing J, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_30etsqcspauce0gfge7e14vril